Premium
Validation of the European Group for Blood and Marrow Transplantation ( EBMT ) risk score in patients receiving allogeneic hematopoietic stem cell transplantation at a single center in Japan
Author(s) -
Numata Ayumi,
Tanaka Masatsugu,
Matsumoto Kenji,
Takasaki Hirotaka,
Tachibana Takayoshi,
Fujimaki Katsumichi,
Sakai Rika,
Fujisawa Shin,
Tomita Naoto,
Fujita Hiroyuki,
Maruta Atsuo,
Ishigatsubo Yoshiaki,
Kanamori Heiwa
Publication year - 2014
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.12324
Subject(s) - medicine , transplantation , cumulative incidence , hematopoietic stem cell transplantation , single center , incidence (geometry) , hematopoietic cell , framingham risk score , surgery , gastroenterology , stem cell , haematopoiesis , disease , physics , biology , optics , genetics
Abstract We validated the European Group for Blood and Marrow Transplantation ( EBMT ) risk score in 273 consecutive adult patients receiving allogeneic hematopoietic stem cell transplantation between 2000 and 2010 at our center. The patients were divided into four groups according to the EBMT risk score: low risk ( LR , score 0–2), intermediate risk‐1 ( IR ‐1, score 3), intermediate risk‐2 ( IR ‐2, score 4), and high risk ( HR , score 5–7). The five‐yr overall survival of the LR (n = 65), IR ‐1 (n = 67), IR ‐2 (n = 70), and HR (n = 71) groups was 72%, 57%, 41%, and 25%, respectively (p < 0.001). The five‐yr transplant‐related mortality rates were 16%, 30%, 25%, and 36%, respectively (p = 0.07). The five‐yr cumulative incidence of relapse was 20%, 18%, 37%, and 41%, respectively (p < 0.001). In the subgroup analysis, the prognostic value of the EBMT risk score was confirmed in patients undergoing myeloablative conditioning ( MAC ), but not in those undergoing reduced‐intensity conditioning ( RIC ). The results suggest that the EBMT risk score is a useful tool to predict transplant outcome for patients undergoing MAC , but not for those undergoing RIC and may be beneficial for stratifying patients in clinical studies.